CANTON, Mass., Nov. 21, 2016 /PRNewswire/ -- U.S. Representative Joe Kennedy III (MA-4) today visited the Canton, Mass. headquarters of Organogenesis Inc., a global leader in advanced wound care innovation and technologies, to tour its research and development labs and manufacturing facilities, meet with employees, and learn about biotechnology solutions that are improving the lives of millions of Americans battling non-healing, chronic wounds like diabetic foot ulcers (DFUs).
"We applaud Congressman Kennedy's commitment to serving constituents in Massachusetts and are honored to welcome him to Organogenesis to showcase our industry-leading advanced wound care technologies," stated Gary S. Gillheeney, Sr., President & CEO of Organogenesis. "We thank Congressman Kennedy for his service and continued support for Massachusetts' thriving biotechnology community."
The visit coincides with November's Diabetes Awareness Month and nationwide efforts to raise awareness about one of the more serious and lesser known complications of diabetes: Chronic, non-healing diabetic foot ulcers, which are currently a leading cause of amputation in America. Organogenesis' Canton facility produces one of the few FDA-approved, bioactive wound healing therapies for the treatment of diabetic foot ulcers.
Organogenesis' Canton facility manufactures and produces Apligraf®, a U.S. Food and Drug Administration (FDA) approved, bioactive wound healing therapy for the treatment of chronic, non-healing diabetic foot ulcers and venous leg ulcers (VLUs). Advanced, FDA-approved wound care products are becoming increasingly important as the rate of diabetes continues to rise across the country. Currently, 29 million Americans are living with diabetes and many more are living with pre-diabetic conditions. Approximately 10 percent of those with diabetes will develop a DFU, which if left untreated can lead to infection and possibly the amputation of a toe, foot, or leg.
Organogenesis also manufactures PuraPly™ and PuraPly Antimicrobial™, FDA 510(k)-cleared Class II medical devices indicated for acute and chronic wound management across a wide variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, and venous and diabetic ulcers.
"For patients across our country suffering from chronic wounds, the innovation taking place in the labs of Organogenesis will help bring treatment and healing," said Congressman Joe Kennedy III. "As we work to support our Commonwealth's thriving biotechnology industry, hearing from executives and employees will guide my efforts in Congress. I thank Gary Gillheeney and the entire Organogenesis team for welcoming me today and for continuing to focus on pushing the boundaries of medical research."
Organogenesis employs approximately 600 people between its headquarters in Canton, Mass., its Dermagraft manufacturing facility in La Jolla, Calif., and its national field sales force. Recently, the company underwent an expansion to support the company's commercial operations, sales force, PuraPly product line, and new product development.
Massachusetts-based Organogenesis Inc. is a global leader in advanced wound care innovation and technologies, including bio-active wound healing and tissue regeneration. Organogenesis' portfolio of products includes FDA-approved Apligraf® and Dermagraft®, the best-in-class products for bio-active wound healing, and recently introduced FDA-cleared PuraPly Antimicrobial™, which advances wound management for a wide variety of wound types. For more information, please visit www.organogenesis.com.
SOURCE Organogenesis Inc.